<DOC>
	<DOCNO>NCT00477529</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLTs ) ABI-008 give every 3 week ; characterize toxicity ABI-008 ; determine pharmacokinetic parameter ABI-008 give every-3-week schedule .</brief_summary>
	<brief_title>ABI-008 Trial Patients With Hormone-refractory Prostate Cancer</brief_title>
	<detailed_description>Detailed description necessary .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Each subject must meet follow criterion enrol study . 1 . Patients must histologically cytologically confirm adenocarcinoma prostate clinically refractory hormone therapy . 2 . Zubrod Performance Status 01 . 3 . At time enrollment , patient must evidence progressive metastatic disease , either : Measurable disease level serum PSA OR Nonmeasurable disease PSA ≥ 5 ng/ml . Patients PSA ≥ 5 ng/ml radiographic evidence metastatic prostate cancer eligible . 4 . Patients must demonstrate evidence progressive disease since recent change therapy . Progressive disease define one following ( measurable disease , bone scan , PSA progression ) : Measurable Disease Progression Bone Scan Progression PSA Progression 5 . Serum testosterone ≤ 50 ng/ml , determine within two week prior start treatment . 6 . Maintaining castrate status : Patients undergone surgical orchiectomy continue medical therapy [ e.g . gonadotropin release hormone analog ( GnRH analog ) ] maintain castrate level serum testosterone . 7 . Megestrol acetate ( MEGACE® ) treatment may continue patient stable dos drug . 8 . Age &gt; 18 year age . 9 . Four week since major surgery . 10 . The following restriction prior therapy metastatic disease apply : No prior chemotherapy regimen metastatic disease . No one prior course palliative radiotherapy . Up one prior treatment nonchemotherapeutic agent ( e.g. , kinase inhibitor , immunotherapeutic agent , etc ) permit treatment metastatic disease . No prior radioisotope therapy Strontium89 , Samarium similar agent . One prior neoadjuvant adjuvant chemotherapy regimen permit give 3 year ago . 11 . No limitation prior hormonal therapy . 12 . Patients therapy least 4 week prior study drug administration . 13 . Life expectancy ≥ 3 month . 14 . Patients must sign informed consent document state understand investigational nature propose treatment . 15 . Required Initial Laboratory Data : WBC ≥ 3,000/µl ANC ≥ 1,500/µl Platelet count ≥ 100,000/µl Creatinine ≤ 1.5 x Total Bilirubin ≤ ( exception make patient Gilbert 's Disease ) SGOT ( AST ) ≤ 1.5 x SGPT ( ALT ) ≤ 1.5 x 16 . Men whose sexual partner childbearing age must agree use adequate contraception ( hormonal barrier method birth control ) duration study participation . 17 . If obese ( weight &gt; 20 % ideal body weight ) patient must treat dos calculate use adjust BSA . Subjects meet follow criterion exclude study . 1 . Patients may receive investigational agent . 2 . Patients may continue daily MultiVitamin , low dose ( ≤ 400 IU qd ) Vitamin D , Calcitrol ( ≤ 0.5 mcg qd ) , calcium supplement , herbal , alternative food supplement ( i.e . PCSpes , Saw Palmetto , St John Wort , etc . ) must discontinue registration . 3 . Patients stable dos bisphosphonates , develop subsequent tumor progression , may continue medication.However , patient may initiate bisphosphonate therapy prior study 4 . Patients know brain metastasis . 5 . Patients history allergic reaction attribute solventbased docetaxel ( Taxotere ) . 6 . Patients significant cardiovascular disease include congestive heart failure , active angina pectoris recent myocardial infarction ( within last 6 month ) . 7 . Patients `` currently active '' second malignancy nonmelanoma skin cancer . 8 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 9 . HIVpositive patient receive combination antiretroviral therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>